Guo Haiping, An Jun, Li Shanshan, Ding Beichuan, Zhang Zhiguo, Shu Wei, Shang Yuanyuan, Wang Yi, Cheng Ken, Wang Yufeng, Xue Zhongtan, Ren Weicong, Pan Junhua, Luo Tao, Pang Yu
Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Postal No 9, Beiguan Street, Tongzhou District, Beijing 101149, PR China.
Medical Record Department, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing 101149, PR China.
J Infect Public Health. 2023 Aug;16(8):1193-1200. doi: 10.1016/j.jiph.2023.05.020. Epub 2023 May 24.
In this study, we utilized whole genome sequencing (WGS) of clinical extremely drug-resistant tuberculosis (EDR-TB) strains collected during 2014-2020 in Beijing to detect clustered strains.
A retrospective cohort study was conducted by inclusion of EDR-TB patients with positive cultures in Beijing between 2014 and 2020.
A total of 95 EDR-TB patients were included in our analysis. Up on the WGS based genotyping, 94 (94/95, 98.9%) out of 95 were identified as lineage 2 (East Asia). The pairwise genomic distance analysis identified 7 clusters, ranging in size from 2 to 5 isolates. The clustering rate of EDR-TB was 21.1%; while no patients had significantly higher odds of clustering. All isolates harbor rpoB RRDR mutations that confer RIF resistance and katG or inhA promoter mutations that confer INH resistance. Of 95 EDR-TB isolates, a total of 15 mutation types were recorded in the transcriptional regulator mmpR5. In vitro susceptibility testing results revealed that 14 (14/15, 93.3%) out of 15 mutation types were resistant to CFZ; whereas only 3 (3/15, 20.0%) showed resistance to BDQ. Interestingly, 12 isolates harbored mutations within rrl locus, whereas only mutations at positions 2294 and 2296 conferred CLA resistance. Favorable outcomes of EDR-TB patients were positively associated with more effective drugs in the regimes.
WGS data demonstrate limited transmission of EDR-TB in this metropolis city. WGS-based drug susceptibility predictions will bring benefits to EDR-TB patients to formulate optimal therapeutic regimens.
在本研究中,我们利用2014 - 2020年在北京收集的临床极端耐药结核病(EDR-TB)菌株的全基因组测序(WGS)来检测聚集菌株。
通过纳入2014年至2020年在北京培养阳性的EDR-TB患者进行回顾性队列研究。
我们的分析共纳入了95例EDR-TB患者。基于WGS的基因分型,95例中的94例(94/95,98.9%)被鉴定为2型谱系(东亚)。成对基因组距离分析确定了7个簇,大小从2到5个分离株不等。EDR-TB的聚集率为21.1%;且没有患者有明显更高的聚集几率。所有分离株都携带赋予利福平耐药性的rpoB耐药决定区(RRDR)突变以及赋予异烟肼耐药性的katG或inhA启动子突变。在95株EDR-TB分离株中,转录调节因子mmpR5共记录到15种突变类型。体外药敏试验结果显示,15种突变类型中的14种(14/15,93.3%)对氯法齐明(CFZ)耐药;而只有3种(3/15,20.0%)对贝达喹啉(BDQ)耐药。有趣的是,12株分离株在rrl基因座内有突变,而只有2294和2296位的突变赋予氯法齐明(CLA)耐药性。EDR-TB患者的良好结局与治疗方案中更有效的药物呈正相关。
WGS数据表明在这个大都市中EDR-TB的传播有限。基于WGS的药敏预测将有助于EDR-TB患者制定最佳治疗方案。